At-Home Diagnostic Testing Markets and Trends (COVID-19, FOB, Glucose, HIV and Other Tests), 2023

Table of Contents

Chapter 1: Executive Summary

• Industry at a Glance
• Scope and Methodology
• Size and Growth of the Market
  • Figure 1-1: Global Home IVD Market, by Key Segment (Glucose/HbA1c, COVID-19, Other, Genetic), 2019-2022
• Key Issues and Trends Affecting the Market
• Competitive Outlook
• Conclusion Highlights

Chapter 2: Introduction

• Overview
• Issues and Trends
• COVID-19
  • Figure 2-1: Home COVID-19 Test Distribution of Sales by Vendor (Abbott Diagnostics, Becton Dickinson, OraSure Technologies, Siemens Healthineers, Quidel, Others)
• Insurance for Home Tests
  • Figure 2-2: Diabetes State Mandates - State-Level Insurance Mandates for Benefits, ACA Marketplace Coverage
• Home IVD Testing Drivers and Challenges
  • Figure 2-3: Benefits to Home Testing vs. Challenges in Home Testing
• Genetics
  • Table 2-1: Home Genetic Laboratory Testing, Market Drivers and Barriers
• Home Collection

Chapter 3: At-Home IVD Tests

• Introduction
• Diabetes
  • Table 3-1: Selected Glucose At-Home Testing Meter Innovations
• Pregnancy and Fertility
• Infectious Disease
• HIV
• COVID-19
• COVID-19 & Flu
  • Table 3-2: Selected COVID- 19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2
• Coagulation
• Fecal Occult Blood
• Cholesterol
• Drugs of Abuse
• At-Home IVD Test Market by Test Type
  • Table 3-3: Global At-Home IVD Market by Test Type (Glucose, Infectious Disease, Other), 2022 ($BN)
  • Figure 3-1: Global At-Home IVD Market by Distribution of Sales by Segment (Glucose, COVID-19+, HIV, Other Infections, Cholesterol, Drug of Abuse, Coagulation, FOB, Pregnancy & Fertility, Other), 2022
• At-Home IVD Tests Market by Sample Type
  • Table 3-4: Global At-Home IVD Market by Sample Type (Blood, Nasal, Oral/Saliva, Stool, Urine, Other), 2022 ($BN)
  • Figure 3-2: Global At-Home IVD Market by Distribution of Sales by Sample Type (Blood, Urine, Oral/Saliva, Nasal, Stool, Other), 2019 and 2022
  • Figure 3-3: Year-over-Year Growth for At-Home IVD Markets (Cholesterol, Coagulation, COVID-19, Drugs of Abuse, FOB, Glucose, HIV, Other Infections, Pregnancy & Fertility, Other), 2020-2021 and 2021-2022 (%)
• Blood Samples
  • Figure 3-4: Estimated Distribution of Blood Sample Sales by Test Type (Cholesterol, Coagulation, Glucose, Other), 2022 (%)
• Urine Samples
  • Figure 3-5: Estimated Distribution of Urine Sample Sales, by Test Type (Drug of Abuse, Infectious Disease, Pregnancy, Other), 2022 (%)
• Oral/Saliva Samples
  • Figure 3-6: Estimated Distribution of Oral/Saliva Sample Sales by Test Type (COVID-19, Drug of Abuse, HIV, Other), 2022 (%)
• Nasal Samples
  • Figure 3-7: Estimated Distribution of Nasal Sample Sales by Test Type (COVID-19, Other), 2022 (%)
• Stool Samples
  • Figure 3-8: Estimated Distribution of Stool Sample Sales by Test Type (FOB, Other), 2022 (%)
• Other

Chapter 4: Home Collection IVD Tests

• Introduction
• Pregnancy and Fertility
• Infectious Disease
• HIV
• HPV and other STDs
• COVID-19
• COVID-19 & Flu
  • Table 4-1: Selected Molecular EUA Tests for COVID-19
• Fecal Occult Blood
• Cholesterol
• Genetics
• Home Collection IVD Tests by Test Type
  • Table 4-2: Global Home Collection IVD Market by Test Type (Genetics, Infectious Disease, Other Areas), 2022 ($BN)
  • Figure 4-1: Global Home IVD Market by Distribution of Sales by Segment (Cholesterol, Coagulation, COVID-19, Drug of Abuse, Genetic, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other), 2022 (%)
• Privacy
• Home Collection Tests by Sample Type
  • Table 4-3: Global Home Collection IVD Market by Sample Type (Blood, Nasal, Oral/Saliva, Stool, Urine, Other), 2022 ($BN)
  • Figure 4-2: Global Home Collection IVD Market by Distribution of Sales by Sample Type (Blood, Urine, Oral/Saliva, Nasal, Stool, Other), 2019 and 2022
  • Figure 4-3: Year-over-Year Growth for Home Collection IVD Markets, by Type (Cholesterol, Coagulation, COVID-19, Drug of Abuse, FOB, Genetic, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other), 2020-2021 and 2021-2022 (%)
• Blood Samples
  • Figure 4-4: Estimated Distribution of Blood Sample Sales by Test Type (Cholesterol, Fertility, Genetic, Glucose/HbA1c, Infectious Disease - STD blood spot, Tumor Market - PSA blood spot, Other - hormone), 2022 (%)
• Urine Samples
  • Figure 4-5: Estimated Distribution of Urine Sample Sales by Test Type (Infectious Disease - STD, Pregnancy/Fertility, Other - Heavy metals, hormone, nutrition), 2022 (%)
• Oral/Saliva Samples
  • Figure 4-6: Estimated Distribution of Oral/Saliva Sample Sales by Test Type (COVID-19, Drug of Abuse, Fertility, Genetic, HIV, Other - hormone, nutrition, medication match), 2022 (%)
• Nasal Samples
  • Figure 4-7: Estimated Distribution of Nasal Sample Sales by Test Type (COVID-19, Other), 2022 (%)
• Stool Samples
  • Figure 4-8: Estimated Distribution of Stool Sample Sales by Test Type (FOB, Infectious Disease - pathogen ID, Other - Heavy metals), 2022 (%)
• Other

Chapter 5: Market Participants

• 23andMe, Inc.
  • Table 5-1: 23andMe Corporate Summary
  • Company Overview
    • Table 5-2: 23andMe Genetic Tests with FDA Marketing Authorization
  • Performance Review
    • Table 5-3: 23andMe Revenue, 2020-2022 ($ millions)

• Abbott Diagnostics
  • Table 5-4: Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-5: Abbott Revenues, 2020-2022 (in millions $)

• AccessBio, Inc.
  • Table 5-6: AccessBio Corporate Summary
  • Company Overview
  • ACON Laboratories, Inc.
    • Table 5-7: ACON Laboratories Corporate Summary
  • Company Overview

• ARKRAY, Inc.
  • Table 5-8: ARKRAY Corporate Summary
  • Company Overview

• Ascensia Diabetes Care Holdings AG
  • Table 5-9: Ascensia Diabetes Care Corporate Summary
  • Company Overview

• Atomo Diagnostics
  • Table 5-10: Atomo Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-11: Atomo Revenues, 2021-2022 (in millions $)

• Becton-Dickinson
  • Table 5-12: Becton-Dickinson Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-13: BD Corporation Revenue, 2020-2022 ($ millions)

• binx health
  • Table 5-14: binx health Corporate Summary
  • Company Overview

• Biomerica, Inc.
  • Table 5-15: Biomerica Corporate Summary
  • Company Overview
  • Company Financials
    • Table 5-16: Biomerica Corporation Revenue, 2020-2022 ($ millions)

• Biosynex SA
  • Table 5-17: Biosynex Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-18: Biosynex Revenues 2021-2022 (in millions $)

• BTNX Inc.
  • Table 5-19: BTNX Corporate Summary
  • Company Overview

• Church & Dwight Co. Inc.
  • Table 5-20: Church & Dwight Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-21: Church and Dwight Revenues, 2020-2022 ($ millions)

• Color Health, Inc.
  • Table 5-22: Color Health Corporate Summary
  • Company Overview

• Cue Health
  • Table 5-23: Cue Health Corporate Summary
  • Company Overview

• Dexcom, Inc.
  • Table 5-24: Dexcom Corporation Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-25: Dexcom Revenues, 2020-2022 ($ millions)

• EasyDNA
  • Table 5-26: EasyDNA Corporate Summary
  • Company Overview

• Everlywell
  • Table 5-27: Everlywell Corporate Summary
  • Company Overview

• Exact Sciences
  • Table 5-28: Exact Sciences Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-29: Exact Sciences Revenues, 2020-2022 ($ millions)

• First Check Diagnostics LLC
  • Table 5-30: First Check Diagnostics Corporate Summary
  • Company Overview

• GlysBy diagnostics
  • Table 5-31: GlysBy Corporate Summary
  • Company Overview

• Helena Laboratories
  • Table 5-32: Helena Laboratories Corporate Summary
  • Company Overview

• Hemosure, Inc.
  • Table 5-33: Hemosure Corporate Summary
  • Company Overview

• LifeScan, Inc.
  • Table 5-34: LifeScan Corporate Summary
  • Company Overview

• Medichecks.com Ltd.
  • Table 5-35: Medichecks Corporate Summary
  • Company Overview

• Myriad Genetics, Inc.
  • Table 5-36: Myriad Genetics Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-37: Myriad Diagnostics Revenue, 2020-2022 ($ millions)

• OraSure Technologies, Inc.
  • Table 5-38: OraSure Technologies Summary
  • Company Overview
  • Performance Review
    • Table 5-39: OraSure Revenues, 2020-2022 ($ millions)

• Polymedco, Inc.
  • Table 5-40: Polymedco Corporate Summary
  • Company Overview

• Preventis GmbH
  • Table 5-41: Preventis Corporate Summary
  • Company Overview

• Prima Lab SA
  • Table 5-42: Prima Corporate Summary
  • Company Overview

• QuidelOrtho Corporation
  • Table 5-43: QuidelOrtho Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-44: QuidelOrtho Revenues, 2020-2022 ($ millions)

• Roche Diagnostic Corporation
  • Table 5-45: Roche Diagnostic Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-46: Roche Diagnostics, 2020-2022 ($ millions)

• Siemens Healthineers GmbH
  • Table 5-47: Siemens Healthineers Corporate Summary
  • Company Overview
  • Performance Review
    • Table 5-48: Siemens Healthineers, 2020-2022 ($ millions)

• Swiss Precision Diagnostics GmbH
  • Table 5-49: Swiss Precision Diagnostics Corporate Summary
  • Company Overview

• Trividia Health
  • Table 5-50: Trividia Health Corporate Summary
  • Company Overview

• VedaLab
  • Table 5-51: VedaLab Corporate Summary
  • Company Overview

Chapter 6: Market Analysis

• Market Overview
  • Figure 6-1: Global Home IVD Market, 2022-2027, 5% CAGR, ($MN)
• Market Segment by Test Type
  • Figure 6-2: Global Home IVD Market by Test Type (Genetic, Glucose/HbA1c, Infectious Disease, Other Areas), 2019-2022 ($MN)
  • Figure 6-3: Global Home IVD Market, by General Test Segment (Genetic, Glucose/HbA1c, Infectious Disease, Other Areas), 2022
• Glucose & HbA1c
  • Table 6-1: Estimated Global Home IVD Glucose & HbA1c Testing Market, 2022-2027 $MN; CAGR 22-27
• Infectious Disease
  • Table 6-2: Estimated Global Home IVD Infectious Disease Testing Market, 2022-2027 $MN; CAGR 22-27
• Other Areas
  • Table 6-3: Estimated Global Home IVD Other Testing Market, 2022-2027 $MN; CAGR 22-27
• Genetic
  • Table 6-4: Estimated Global Home IVD Genetic Testing Market, 2022-2027 $MN; CAGR 22-27
• Market by Distribution
• Market by Region
  • Figure 6-4: Estimated Global Home IVD Testing Market, by Region (APAC, EMEA, United States, Rest of World), 2019-2022
• Competitive Analysis
  • Figure 6-5: Estimated Global Home IVD Testing Market, Vendor Market Share, by Top Five Market Vendors (Abbott, Dexcom, QuidelOrtho, Roche, Siemens Healthineers, Other), 2022